Global Gastro-retentive Drug Delivery System Market Strategic Research Report

Scope of the Report

The global Gastro-retentive Drug Delivery System market size is predicted to grow from US$ 11,360 million in 2025 to US$ 17,527 million in 2032; it is expected to grow at a CAGR of 6.4% from 2026 to 2032.

Gastro-retentive Drug Delivery Systems (GRDDS) are advanced oral pharmaceutical platforms designed to prolong the residence time of a drug formulation in the stomach, enabling sustained, controlled release and site-specific delivery to the upper gastrointestinal tract. Unlike conventional oral dosage forms that empty rapidly from the stomach (typically within 1-2 hours), GRDDS can extend gastric retention for up to 24 hours, significantly improving the bioavailability of drugs with narrow absorption windows, pH-dependent solubility, or instability in the lower GI tract. Key technologies include floating systems (low-density formulations that buoy in gastric fluid), mucoadhesive systems (polymers that adhere to gastric mucosa), swelling/expandable systems (large-format tablets that resist gastric emptying), high-density systems (sinking formulations), and magnetic systems. GRDDS are particularly valuable for treating H. pylori infections, peptic ulcers, and for delivering drugs like ribavirin, metformin, and certain antibiotics. From a value chain perspective, upstream includes functional polymer suppliers (HPMC, carbomers, chitosan), gas-generating agent manufacturers, and excipient providers; midstream involves formulation development, technology platform licensing, scale-up, and manufacturing; downstream demand spans pharmaceutical companies, generic drug developers, and CRO/CDMO service providers.

Global key Gastro-retentive Drug Delivery System players cover Triastek, Inc., Bostal Drug Delivery Co., Ltd., Vivtex Corporation, Clexio Biosciences Ltd., Medimetrics Personalized Drug Delivery, Inc., etc.

This report presents a comprehensive overview of the global Gastro-retentive Drug Delivery System market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Sustained Release
• Controlled Release (Zero-Order)
• Delayed / Pulsatile Release

Segment by Buoyancy Generation Method

• Effervescent (Gas-Generating) System
• Non-Effervescent (Low-Density) System

Segment by Gastric Retention Duration

• Short Retention (< 4 hours)
• Medium Retention (4-12 hours)
• Long Retention (> 12 hours)

Segment by Application

• Anti-infective (H. pylori Eradication)
• Gastroenterology (Peptic Ulcer, GERD)
• Metabolic Disorders (Diabetes)
• Cardiovascular (Hypertension)
• Antiviral Therapy

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Gastro-retentive Drug Delivery System market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Anti-infective (H. pylori Eradication), Gastroenterology (Peptic Ulcer, GERD), Metabolic Disorders (Diabetes) evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact